Email: Office Phone: 318-675-5757
Laboratory Phone: 318-675-7564
Office Fax: 318-675-5764
Postdoctoral Study, The Wistar Institute of Anatomy and Biology
Ph.D., Cell and Molecular Biology, 1976, Rensselaer Polytechnic Institute
B.A., Biology, 1971, Saint Vincent College
Major Research Interests:
Development of Pseudomonas aeruginosa vaccines
Pseudomonas aeruginosa infection is an underappreciated cause of morbidity and mortality. These infections can be life-threatening in immunocompromised populations, cancer patients, the elderly, and patients with cystic fibrosis. Physicians try to protect patients with antibiotic therapy, but the bacteria quickly develop antibiotic resistance. A complementary approach to antibiotic therapy is vaccination. We develop vaccines that protect against Pseudomonas lung infection. Two effective outer membrane protein F (OprF)-based vaccines are called F/I and F/HG. The F/I vaccine consists of three biolistic inoculations of naked DNA sequences for the fusion protein OprF/I. The F/HG vaccine uses a prime-boost strategy with two biolistic inoculations of naked DNA- oprF sequences followed by an intramuscular booster containing the chimeric influenza virus HG10-11. Each vaccine induced a polarized immune response. The F/I vaccine induced antibody-mediated immunity (AMI) while F/HG induced cell-mediated immunity (CMI). AMI in pulmonary Pseudomonas infection is important, but the mechanism for clearance is unknown. We propose to define the mechanisms of antibody protection by identifying antibody isotypes and serum cytokines in infected and F/I-immunized mice that are immune-intact or immune-deficient. Likewise, the role of CMI in Pseudomonas pneumonia is poorly understood. Our F/HG vaccine will allow us to define the mechanism(s) of Pseudomonas -specific, cell-mediated protection in the lungs of infected and immunized mice that are immune-intact or immune-deficient. Defining these mechanisms will allow us to rationally modify immune responses to protect more effectively against pulmonary Pseudomonas infection. As researchers delineate the immune responses to pulmonary Pseudomonas infection in humans, we will be uniquely positioned to modify our vaccines to induce AMI or CMI responses. These rationally designed vaccines tested in a pulmonary chronic infection model will provide guiding principles to prevent and treat more effectively Pseudomonas pneumonia in humans.
Gilleland, H. E., Jr., L. B. Gilleland, J. Staczek, R. N. Harty, A. Garcia-Sastre, O. G. Engelhardt, and P. Palese. 1997. Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa . Behring Institute Mitteilungen (BIM) No. 98:291-301.
Staczek, J., H. E. Gilleland, Jr., L. B. Gilleland, R. N. Harty, A. Garcia-Sastre, O. G. Engelhardt, and P. Palese. 1998. A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection. Infection and Immunity. 66:3990-3994.
Mansouri, E., J. Gabelsberger, B. Knapp, E. Hundt, U. Lenz, K-D Hungerer, H. E. Gilleland, Jr., J. Staczek, H. Domdey and B.-U. von Specht, 1999. Safety and immunogenicity of Pseudomonas aeruginosa hybrid outer Membrane protein F-I vaccine in human volunteers. Infection and Immunity 67(3):1461-1470.
Price, B., D. R. Galloway, B.-U. von Specht, L. B. Gilleland, H. E. Gilleland, Jr., and J. Staczek. 2002. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa . FEMS Immunology and Medical Microbiology. 23(2):33-43.
Staczek, J., L. B. Gilleland, H. C. van der Heyde, H. E. Gilleland, Jr. 2003. DNA-vaccines against chronic lung infections by Pseudomonas aeruginosa. FEMS Immunology and Medical Microbiology 33:89-99.